Sun Chaofan, Yang Xiaohui, Feng Xingzhong
Beijing University of Chinese Medicine, Beijing, 100029, China.
Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100700, China.
Acta Diabetol. 2025 Jun 5. doi: 10.1007/s00592-025-02527-x.
This study aimed to explore the relationships between lipid metabolism indices-the Lipid Accumulation Product (LAP), Visceral Adiposity Index (VAI), Cardiac Metabolic Index (CMI), and Atherogenic Index of Plasma (AIP)-and sarcopenia in individuals aged ≥ 60 years, and to investigate the mediating role of uric acid (UA) in these relationships. The goal was to provide scientific evidence and practical guidance for preventing and treating sarcopenia in older adults.
Data from 2001 participants aged ≥ 60 years in the 2003-2006 National Health and Nutrition Examination Survey (NHANES) were analyzed. Statistical analyses, including logistic regression, restricted cubic splines (RCS), subgroup analysis, and mediation analysis, were conducted to examine the associations among various lipid metabolism indices, UA levels, and sarcopenia.
Multivariable-adjusted models revealed significant inverse associations between lipid metabolism indices and sarcopenia (all P < 0.05). In the fully adjusted model (model III), the adjusted odds ratios (OR) for LAP, VAI, CMI, and AIP were 0.97 (95% CI: 0.97-0.98), 0.78 (0.68-0.89), 0.32 (0.21-0.49), and 0.27 (0.15-0.52), respectively (all P < 0.05). RCS analyses revealed inverse dose-response relationships between lipid metabolism indices and sarcopenia. The ROC analysis revealed that LAP showed the highest diagnostic value among the four indices. Subgroup analyses showed no significant differences in this relationship across different subgroups. Notably, UA partially mediated these associations (mediation proportions: 8.91-20.66%). These findings suggest that maintaining lipid homeostasis and UA levels may offer protective benefits against age-related sarcopenia.
Our findings advance the understanding of the obesity paradox by revealing that higher lipid metabolism indices (LAP, VAI, CMI, AIP) and UA levels are inversely associated with sarcopenia in the elderly, with UA partially mediating these protective effects. These results highlight the importance of maintaining lipid and UA levels within normal ranges as a potential novel strategy for preventing and managing sarcopenia. These findings suggest that reconsidering these biomarkers in the management of geriatric muscle health is necessary, highlighting their importance in understanding and addressing the pathogenesis of sarcopenia in aging populations.
本研究旨在探讨脂质代谢指标——脂质蓄积产物(LAP)、内脏肥胖指数(VAI)、心脏代谢指数(CMI)和血浆致动脉粥样硬化指数(AIP)与60岁及以上人群肌肉减少症之间的关系,并研究尿酸(UA)在这些关系中的中介作用。目标是为预防和治疗老年人肌肉减少症提供科学依据和实践指导。
分析了2003 - 2006年美国国家健康与营养检查调查(NHANES)中2001名60岁及以上参与者的数据。进行了包括逻辑回归、受限立方样条(RCS)、亚组分析和中介分析在内的统计分析,以检验各种脂质代谢指标、UA水平与肌肉减少症之间的关联。
多变量调整模型显示脂质代谢指标与肌肉减少症之间存在显著的负相关(所有P < 0.05)。在完全调整模型(模型III)中,LAP、VAI、CMI和AIP的调整优势比(OR)分别为0.97(95%CI:0.97 - 0.98)、0.78(0.68 - 0.89)、0.32(0.21 - 0.49)和0.27(0.15 - 0.52)(所有P < 0.05)。RCS分析显示脂质代谢指标与肌肉减少症之间存在负剂量反应关系。ROC分析显示LAP在四个指标中具有最高的诊断价值。亚组分析显示不同亚组之间在这种关系上没有显著差异。值得注意的是,UA部分介导了这些关联(中介比例:8.91 - 20.66%)。这些发现表明维持脂质稳态和UA水平可能对与年龄相关的肌肉减少症具有保护作用。
我们的研究结果通过揭示较高的脂质代谢指标(LAP、VAI、CMI、AIP)和UA水平与老年人肌肉减少症呈负相关,且UA部分介导这些保护作用,推进了对肥胖悖论的理解。这些结果强调了将脂质和UA水平维持在正常范围内作为预防和管理肌肉减少症的潜在新策略的重要性。这些发现表明在老年肌肉健康管理中重新考虑这些生物标志物是必要的,突出了它们在理解和解决衰老人群肌肉减少症发病机制中的重要性。